Compare · HRTX vs NVO
HRTX vs NVO
Side-by-side comparison of Heron Therapeutics Inc. (HRTX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HRTX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $196.77B, about 1256.8x HRTX ($156.6M).
- Over the past year, HRTX is down 57.3% and NVO is down 39.5% - NVO leads by 17.8 points.
- NVO has been more active in the news (11 items in the past 4 weeks vs 3 for HRTX).
- NVO has more recent analyst coverage (25 ratings vs 4 for HRTX).
- Company
- Heron Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $0.82-5.04%
- $44.05-3.39%
- Market cap
- $156.6M
- $196.77B
- 1M return
- -31.83%
- +4.41%
- 1Y return
- -57.32%
- -39.50%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 3
- 11
- Recent ratings
- 4
- 25
Heron Therapeutics Inc.
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing HTX-011, an investigational, dual-acting, and fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam, which is in Phase III clinical trials for pain management; and HTX-034, which is in Phase Ib/II clinical trials for postoperative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest HRTX
- SEC Form 10-Q filed by Heron Therapeutics Inc.
- Heron Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance
- Chief Operating Officer Hensley Mark Earl converted options into 125,000 shares, increasing direct ownership by 1,062% to 136,770 units (SEC Form 4)
- Chief Operating Officer Hensley Mark Earl converted options into 11,770 shares (SEC Form 4)
- EVP, Chief Development Officer Forbes William P converted options into 23,464 shares, increasing direct ownership by 13% to 209,111 units (SEC Form 4)
- EVP, Chief Financial Officer Duarte Ira converted options into 25,229 shares, increasing direct ownership by 17% to 252,128 units (SEC Form 4)
- Chief Executive Officer Collard Craig A converted options into 84,810 shares, increasing direct ownership by 14% to 757,885 units (SEC Form 4)
- SEC Form DEFA14A filed by Heron Therapeutics Inc.
- SEC Form DEF 14A filed by Heron Therapeutics Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates